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Summary 
 
 
 
 
XLR-11 ([1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone) is a 
synthetic constituent found in herbal smoking mixtures that are sold under a variety of brand 
names. It is common for retailers to purchase bulk quantities of the synthetic substance and to add 
the synthetic material to a variety of vegetable matter used as the plant base.  
 
XLR-11 has been demonstrated to be a full agonist at human G-protein coupled CB1 and CB2 
receptors. Investigations carried out in vitro demonstrated functional and mechanistic similarities 
to Δ9-THC. In some assays, XLR-11 displayed a higher potency than Δ9-THC in its ability to 
mediate Δ9-THC-like effects. When investigated in vivo, XLR-11 also displayed Δ9-THC-like 
effects (sometimes more potent) that were attenuated by rimonabant.  
 
The available data suggest XLR-11 to display abuse liability. Further studies are needed to assess 
dependence potential. Severe adverse effects have been associated with a range of synthetic 
cannabinoids but the total numbers of cases that have been specifically linked to XLR-11 are more 
limited. Adverse effects associated with XLR-11 included acute kidney injury, low body 
temperature, rigid muscle tone, back or abdominal pain, elevated peak systolic blood pressure, 
slurred speech, lack of convergence, and body and eyelid tremors. One case of acute cerebral 
ischemia and infarction was reported although XLR-11 was not detected in blood and urine. 
Commonly reported adverse reactions associated with a range of synthetic cannabinoids frequently 
include agitation, cardiovascular events including tachycardia and hypertension, hallucination, 
nausea/hyperemesis, seizures and hypokalaemia. Chest pain, myoclonia and psychiatric 
complications were also reported. No therapeutic and medical use could be identified.    
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1.   Substance identification  
A. International Nonproprietary Name (INN) 
Not applicable. 
B. Chemical Abstract Service (CAS) Registry Number 
1364933-54-9 
C. Other Chemical Names 
Not applicable (see Section 2). 
D. Trade Names 
Not applicable. 
E. Street Names 
XLR-11, 5F-UR-144, TMCP-2201, 5-FUR-144, ‘Spice’, ‘synthetic cannabis’. This 
substance is a constituent found in a range of herbal mixtures that are sold using 
rapidly changing product names (e.g. ‘Maya 2012’, ‘Peace’, ‘Vegas Titanium’,1 
‘Bizarro Blueberry’, ‘Colorado’, ‘Funky Green Stuff (Reggie’s Blend)’, ‘Hammer 
Head’, ‘iBlown 4G’, ‘Sunshine Daydream’, ‘Sunshine Nightmare’,2 ‘Mr. Happy’, 
‘Clown Loyal’, ‘Lava’3, ‘WTF’4).       
F. Physical Appearance 
XLR-11 is a white crystalline solid and forms large prismatic crystals.
5
 
G. WHO Review History 
XLR-11 has not been previously pre-reviewed or critically reviewed. A direct 
critical review is proposed based on information brought to WHO’s attention that 
XLR-11 is clandestinely manufactured, of especially serious risk to public health 
and society, and of no recognized therapeutic use by any party. Preliminary data 
collected from literature and different countries indicated that this substance may 
cause substantial harm and that it has no medical use. 
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2. Chemistry 
A. Chemical Name 
IUPAC Name: [1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
CA Index Name: [1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
B. Chemical Structure 
Free base: 
 
 
Molecular Formula: C21H28FNO 
Molecular Weight: 329.46 g/mol  
C. Stereoisomers 
Not applicable. 
D. Methods and Ease of Illicit Manufacturing 
Information about illicit manufacturing is unavailable. One approach to XLR-11 
synthesis is based on a standard acylation reaction of indole with 2,2,3,3-
tetramethylcyclopropanecarbonyl chloride (a) followed by N-alkylation with 1-
bromo-5-fluoropentane (b)
5
 similar to the preparation reported for other 3-(2,2,3,3-
tetramethylcyclopropanecarbonyl)indole analogs (e.g.
6, 7
). Illicit manufacturing of 
this substance is expected to be simple and straightforward. 
 
 
O
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F
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E. Chemical Properties 
Melting point: 76-77 °C (i-PrOH/H2O)
5
 
Boiling point: Not reported. 
Solubility: ~0.2 mg/mL in 1:4 EtOH:phosphate-buffered saline (pH 7.2); ~30 
mg/mL in EtOH, DMF, and DMSO.
8
 
F. Identification and Analysis  
A range of routine and standard methods can be applied for the chemical analysis of 
XLR-11 in bulk form (e.g. spiked plant matter, powder and liquids). More sensitive 
analytical techniques may be needed (e.g. single or multistage mass spectrometry) 
for the detection of this substance in biological matrices with low concentration. For 
the analysis of biological fluids such as urine, the detection of the unchanged parent 
molecule may be challenging, thus, requiring the detection of XLR-11 metabolites 
instead. Table 1 (Annex 2) provides a list of representative examples published in 
the scientific literature. 
 
3. Ease of Convertibility Into Controlled Substances 
No information available. 
 
4. General Pharmacology 
A. Routes of administration and dosage 
XLR-11, in its pure form but mostly as a constituent in herbal mixtures, is most 
commonly smoked but reliable data about dosage are unavailable. The variations in 
drug composition and quantities frequently observed with many smoking mixtures 
(e.g.
1
) make such an estimation impossible for users as well despite what might be 
written on a product label.    
B. Pharmacokinetics 
One key finding associated with the transformation of XLR-11 in biological fluids 
includes the fact that several metabolites are identical to those formed from UR-144 
metabolism (including formation of UR-144 as a metabolite of XLR-11) and that 
the detection of XLR-11 metabolites in urine should be targeted rather than 
attempting to detect the parent, unchanged compound. XLR-11, equivalent to what 
is observed with UR-144, undergoes heat-induced degradation during smoking (and 
some forms of instrumental analysis such as gas chromatography), which yields the 
formation of 1-(1-(5-fluoropentyl)-1H-indol-3-yl)-3,3,4-trimethylpent-4-en-1-one, 
thus, presenting an additional target for bioanalytical applications. The extent to 
which the formation of UR-144 metabolites affects the detection window related to 
XRL-11 intake remains to be investigated.   
 
Several in vitro metabolism studies have been published in the scientific literature, 
which included the use of human hepatocytes,
9
 human hepatocellular carcinoma 
cells (HepaRG)
10
, pooled human liver microsomes (pHLMs)
11, 12
 and recombinant 
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human CYP enzymes.
12
 In the case where human hepatocytes were employed 
(phase I and phase II, analysis after 1h and 3 h), more than of 25 biotransformation 
products were detected resulting from hydroxylation, carboxylation, hemiketal and 
hemiacetal formation, dehydration, and glucuronidation of some oxidative 
metabolites, including oxidative defluorination. Major metabolites identified 
included 2’-carboxy-XLR-11, UR-144 pentanoic acid, 5-hydroxy-UR-144, 2’-
carboxy-UR-144 pentanoic acid, 2’-hydroxy-XLR-11 glucuronide and 1’-hydroxy-
XLR-11 glucuronide, respectively.
9
 The incubation of XLR-11 in HepaRG cells for 
48 h followed by enzymatic hydrolysis revealed the detection of 12 metabolites, 
which included UR-144 pentanoic acid and 5-hydroxy-UR-144.
10
 Incubation with 
pHLMs (analysis after 15 min and 90 min) confirmed the involvement of 
hydroxylation, dioxidation followed by internal dehydration, carboxylation, N-
dealkylation, oxidative defluorination and various combinations thereof. 
Furthermore, it was shown that CYP3A4 was the major isozyme involved in the 
CYP mediated transformation of XLR-11.
12
 In another in vitro study using pHLMs 
(2 h incubation), the dominating metabolite was identified as 5-hydroxy-UR-144. A 
comparison with UR-144 transformation under identical conditions suggested a 
different ratio between 5-hydroxy-UR-144 and 4-hydroxy-UR-144 that was not 
detected following XLR-11 incubation.
11
 
 
The analysis of male ICR mice urine samples obtained from intravenous injection 
of XLR-11 in the tail vein revealed the presence of monohydroxylated metabolites 
along with their glucuronide conjugates including 5-hydroxy-UR-144. The 
defluorinated analog UR-144 and other carboxylated species have also been 
detected.
13
 Interestingly, the main metabolites detected in an authentic urine sample 
obtained from a XLR-11 user included the N-(5-hydroxypentyl) and the N-
pentanoic acid derivatives of the XLR-11 degradant mentioned above.
10
 The 
analysis of six authentic urine specimens both (with and without enzymatic 
hydrolysis) revealed the detection of 19 metabolites, also displaying oxidative 
defluorination, hydroxylation, carboxylation, dehydrogenation, glucuronidation, 
and combinations of these reactions. The majority of metabolites were identified as 
the transformation products based on the XLR-degradant.
11
  
 
The detection of the parent molecule in blood however, has been demonstrated in a 
number of clinical cases.
14, 15
 In an analysis report on hair samples associated with 
XLR-11 consumption the detected species were XLR-11, UR-144, 5-hydroxy-UR-
144, UR-144 pentanoic acid, 4-hydroxy-UR-144 and 4-hydroxy-XLR-11, 
respectively.
16
 Unchanged XLR-11, hydroxylated metabolites and the XLR-11 
degradant could also be detected in oral fluid samples associated with the presence 
of XLR-11 and UR-144.
17
  
C. Pharmacodynamics 
Information about the effects are currently available from a number of in vitro and 
in vivo assays is summarized in Tables 2 and 3, which demonstrate effects also 
observed with Δ9-THC, which, when tested under in vivo conditions, could be 
attenuated with rimonabant.  
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For example, radioligand displacement studies with hCB1 and hCB2 (HEK-293) 
using [
3
H]CP-55,940, [
3
H]SR-144,528 and [
3
H]rimonabant confirmed that XLR-11 
showed higher affinity to both receptor subtypes in the low nanomolar range 
compared to Δ9-THC (Table 2) with a ~11-fold selectivity toward CB2. Both 
receptors were also activated at low nanomolar concentrations ([
35
S]GTPγS 
binding) and XLR-11 acted as a full agonist.
13
 XLR-11 was more potent and 
showed higher efficacy than Δ9-THC in the ability to activate G protein-gated 
inwardly rectifying K
+ 
channels (GIRKs).
5
 XLR-11 was also found to be more or 
less equipotent in the ability to inhibit CB1 receptor mediated inhibition of 
glutamate release in mouse hippocampal slice preparations (blocked by CB1 
receptor antagonists AM251 or PIMSR1), although JWH-018 was about 67-fold 
more potent (Table 2).
18
 In vivo studies revealed that the effects of XLR-11 were 
mechanistically consistent with Δ9-THC (Table 3).  
 
Similar to UR-144,
19
 XLR-11 has been reported to convert into 1-(1-(5-
fluoropentyl)-1H-indol-3-yl)-3,3,4-trimethylpent-4-en-1-one as a consequence of 
exposure to heat (e.g. during chemical analysis by gas chromatography-based 
systems) or smoking,
20
 which means that it can also undergo biotransformation (see 
Section 4B). Information about the pharmacodynamic properties of this degradant is 
currently unavailable. Interestingly, the metabolite common to both XLR-11 and 
UR-144 (5-hydroxy-UR-144) was identified as a CB2 selective agonist
5, 7
 but the 
extent to which this impacts on the overall drug effects in users of XLR-11 is 
unclear. 
38
th
 ECDD (2016) Agenda item 4.12  XLR-11 
 
 
 
Page 12 of 33 
Table 2. XLR-11 in-vitro data  Ref 
Receptor binding: 
a
  
 
XLR-11: CB1 Ki = 24 nM ([
3
H]CP-55,940), 234 nM ([
3
H]SR-144,528) and CB2: Ki = 2.1 nM ([
3
H]CP-55,940).  
 
Δ9-THC (data from previous study): CB1 Ki = 67 nM ([
3
H]CP-55,940), 764 nM ([
3
H]SR-144,528) and CB2 Ki = 36 nM ([
3
H]CP-55,940).  
 
Rimonabant (data partially from previous study): CB1 Ki = 6 nM ([
3
H]CP-55,940), 1.8 nM ([
3
H]SR-144,528) and CB2 Ki = 702 nM ([
3
H]CP-55,940).  
CP-55,940 (data partially from previous study): CB1 Ki = 1 nM ([
3
H]CP-55,940), 31 nM ([
3
H]SR-144,528) and CB2 Ki = 0.7 nM ([
3
H]CP-55,940).  
UR-144: CB1 Ki = 29 nM ([
3
H]CP-55,940), 368 nM ([
3
H]SR-144,528) and CB2 Ki = 4.5 nM ([
3
H]CP-55,940).  
 
[
35S]GTPγS binding (all three tested compounds were full agonists at both receptors): b 
 
CB1 receptors: XLR-11: ED50 = 159 nM; CP-55,940: ED50 = 25 nM; UR-144: ED50 = 98 nM. 
CB2 receptors: XLR-11: ED50 = 145 nM; CP-55,940: ED50 = 23 nM; UR-144: ED50 = 334 nM. 
Wiley et al.
13
 
Functional activity: 
c
 
 
CB1 receptors: XLR-11: ED50 = 98 nM; WIN-55,212-12: ED50 = 284 nM; Δ
9
-THC: ED50 = 250 nM; UR-144: ED50 = 421 nM. 
CB2 receptors: XLR-11: ED50 = 83 nM; WIN-55,212-12: ED50 = 62 nM; Δ
9
-THC: ED50 = 1157 nM; UR-144: ED50 = 72 nM. 
 
Efficacy relative to WIN 55,212-2 to stimulate hyperpolarization (= 100%): 
 
CB1 receptors: XLR-11: 110%; Δ
9
-THC: 51%; UR-144: 94% 
CB2 receptors: XLR-11: 117%; Δ
9
-THC: 13% (at 10 μM); UR-144: 104% 
Banister et al.
5
 
Receptor binding: 
d
  
 
XLR-11: CB1 IC50 = 7.92 nM; UR-144: IC50 = 578.5 nM. 
 
Functional activity: 
d
  
 
XLR-11: CB1 EC50 = 359 nM (efficacy 104.95%); UR-144: EC50 = 1295 nM (efficacy 95.28%). 
Gatch et al.
21
 
Functional activity: 
e
  
 
cAMP inhibition assay: XLR-11: EC50 = 3981 nM (efficacy 65%); WIN 55,212-2: EC50 = 31.6 nM (efficacy 65%); CP-55,940 EC50 = 316 nM (efficacy 
47%). CB1 agonist-mediated reductions in forskolin-stimulated cAMP levels were blocked in the presence of rimonabant.  
 
CB1-induced suppression of Ca
2+
 spiking in cultured rat hippocampal neurons. XLR-11 addition (1 and 10 μM) suppressed Ca2+ spiking. WIN-55,212-2 
significantly suppressed Ca
2+
 spiking frequency at 10 μM, but not at 1 μM. WIN 55,212-3 (10 μM) did not suppress Ca2+ spiking to confirm CB1-
induced suppression whereas CP-55,940 suppressed spiking frequency at 10 μM. 
Costain et al.
22
 
 Hoffman et al.
18
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Electrophysiological recordings in mouse hippocampal slice preparations: 
f 
 
Maximal inhibition of glutamatergic field excitatory postsynaptic potential (fEPSPs):  
 
Δ9-THC: EC50 = 707 nM (39% at 1 μM). 
XLR-11: EC50 = 933 nM (41% at 2 μM).  
JWH-018: EC50 = 14 nM (46% at 100 nM). 
Effects were reversed by addition of the neutral CB1 antagonist PIMSR1.  
Slices incubated for 90 min with XLR-11 (1μM) showed significantly reduced long-term potentiation.  
Functional activity: 
g
  
 
CB1-induced suppression of Ca
2+
 spiking in a hippocampal neurons grown on a multi-electrode array (MEA) dish.  
XLR-11 (10 μM) significantly reduced Ca2+ mediated spikes in neurons grown on MEAs compared to DMSO at the 40, 60 and 80 min time points. A 
CB1-mediated mechanism was implicated given that rimonabant (5 μM) reversed the suppression. 
Tauskela et al.
23
 
 
a
 Ref
13
: hCB1 and hCB2 (HEK-293); [
3
H]CP-55,940 (7.2 nM) or [
3
H]rimonabant (2 nM) used for displacement (nonspecific binding determined by inclusion of 10 μM 
unlabeled CP-55,940 or rimonabant); concentration of [
3
H]SR-144,528 not reported.  
b
 Ref
13: incubation of mixture containing test drug (0.25 nM to 20 μM), GDP (20 μM), GTPγ[35S] (100 pM), and hCB1 and hCB2 membrane preparations from HEK-293 
cells.  
c
 Ref
5
: hCB1 and hCB2 receptors in stably transfected mouse AtT20 neuroblastoma cells; FLIPR membrane potential assay (blue) used for quantitative determination of K
+
 
flux (hyperpolarization) linked to G-protein activation: G-protein-gated inwardly rectifying K
+
 channels (GIRKs); plates were incubated at ambient CO2 for 45 min at 37 °C; 
WIN 55,212-2 produced maximal decrease in fluorescence, corresponding to hyperpolarization of 29% in AtT20-CB1 cells and 31% in AtT20-CB2 cells. Comparison of test 
drugs was normalized against the WIN 55,212-2 response. WIN 55,212-2 showed a 4-lod preference for stimulating hyperpolarization in AtT20-CB2 cells compared to 
AtT20-CB1 cells.  
d
 Ref
21
: Assays carried out by NovaScreen (PerkinElmer, Waltham, Massachusetts, USA) under contract with the National Institute on Drug Abuse Addiction Treatment 
Discovery Program; hCB1 receptors expressed in HEK-293 (binding) and CHO cells (functional activity). Further details not reported.  
e
 Ref
22: GloSensor™ cAMP assay; HEK293T cells transiently transfected with pGloSensor-22F  and pcDNA6-CNR1; efficacy (% inhibition) relative to full agonist WIN-
55,212-2. Synthetic cannabinoids were added 12 min prior to the addition of 10 μM forskolin. Luminescence was determined 15 min after forskolin addition; data were 
normalized to vehicle readings. Low-density primary hippocampal cultures were loaded with a Ca
2+
 indicator and exposed to low Mg
2+
 buffer to induce spontaneous, 
transient increases in intracellular Ca
2+
 levels (Ca
2+ 
spikes). 
f
 Ref
18
: Studies employed 4-to 6 week-old male wildtype C57BL6 mice or CB1
+/+
 and CB1
-/-
 mice bred on a C57BL6 background. The selective adenosine A1 receptor 
antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 200 nM), was included in the artificial CSF (aCSF) throughout incubation and recordings to avoid disruption CB1R-
mediated inhibition of glutamate release. During electrophysiological recordings, a switch between control aCSF and drug-containing aCSF was performed. Field excitatory 
postsynaptic potential (fEPSP) responses were monitored.  
g
 Ref
23
: each multi-electrode array served as its own internal control: two 20 min baseline recordings were performed prior to acquiring four 20 min recordings with a 
cannabinoid or DMSO vehicle present; online extracellular spike detection was used.  
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Table 3. In vivo assay data for XLR-11
 
Behaviour / physiology / neurochemistry Ref 
 
Tetrad test: 
a 
 
Spontaneous activity: 
XLR-11: ED50 = 0.9 μmol/kg 
Δ9-THC: ED50 ED50 = 15 μmol/kg (positive control)  
UR-144: ED50 = 1.0 μmol/kg 
 
Drop in total counts compared to vehicle condition with significant difference (p < 0.05): 
XLR-11: 3 mg/kg 
Δ9-THC: 30 mg/kg 
UR-144: not considered significant. 
 
Percent maximum possible antinociceptive effect: 
XLR-11: ED50 = 3.3 μmol/kg 
Δ9-THC: ED50 = 12 μmol/kg (positive control) 
UR-144: ED50 = 2.6 μmol/kg 
 
Compared to vehicle condition with significant difference (p < 0.05): 
XLR-11: 3 mg/kg 
Δ9-THC: 3, 10 and 30 mg/kg 
UR-144: 3 mg/kg 
 
Rectal temperature (hypothermia): 
XLR-11: ED50 = 0.6 μmol/kg 
Δ9-THC: ED50 = 4 μmol/kg (positive control) 
UR-144: ED50 = 0.6 μmol/kg 
 
Drop in rectal temperature compared to vehicle condition with significant difference (p < 0.05): 
 
XLR-11: 0.1, 1 and 3 mg/kg 
Δ9-THC: 1, 3, 10 and 30 mg/kg 
UR-144: 1 and 3 mg/kg 
 
Ring immobility (catalepsy): 
XLR-11: ED50 = 0.6 μmol/kg 
Δ9-THC: ED50 = 3 μmol/kg (positive control) 
UR-144: ED50 = 1.0 μmol/kg 
 
Percentage increase in immobility compared to vehicle condition with significant difference (p < 
0.05): 
 
XLR-11: 0.3, 1 and 3 mg/kg 
Δ9-THC: 1, 3, 10 and 30 mg/kg 
UR-144: 1 and 3 mg/kg 
 
With the exception of the effects of XLR-11 in the ring immobility test, the cannabinoid effects of 
XLR-11 (3 mg/kg) and UR-144 (3 mg/kg) were blocked in the tetrad tests by prior administration 
of rimonabant (3 mg/kg). The effects of Δ9-THC (10 mg/kg) were also attenuated by rimonabant 
but statistical significance (p<0.05) was not reached in the hypothermia test.  
 
Drug discrimination: 
b
 
 
XLR-11: ED50 = 3.5 μmol/kg 
Δ9-THC: ED50 = 5.4 μmol/kg (positive control) 
Wiley et al.
13
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UR-144: ED50 = 7.4 μmol/kg 
 
Rimonbant (3 mg/kg) significantly antagonized substitution of 5.6 mg/kg doses of XLR-11 and 
UR-144. Response rates following agonist-antagonist combination were not significantly affected 
for XLR-11 but significantly decreased (compared to vehicle) for UR-144. 
 
Body temperature: 
c 
 
A moderate, dose-dependent decrease in body temperature was observed for XLR-11 and UR-144 
at 10 mg/kg levels. Terminal fluorination did not induce a change. In comparison, a large 
hypothermic effect (-1.5 °C) was observed following JWH-018 administration (3 mg/kg).  
 
Heart rate: 
c
 
 
A decrease in heart rate was observed for XLR-11 and UR-144 (and other test drugs studied) 
when administered between 0.3 and 10 mg/kg. 
Banister et al.
5
 
 
Locomotor activity: 
d
 
 
XLR-11 (ED50 = 10.29 mg/kg), Δ
9
-THC (ED50 = 11.14 mg/kg) and UR-144 (ED50 = 7.68 mg/kg) 
decreased locomotor activity as dose increased.  
 
Depressant effects of XLR-11 occurred within 10 min after administration and lasted 40-60 min. 
Maximal depressant effects of 10 and 30 mg/kg occurred 10-40 min after injection.  
 
Depressant effects of Δ9-THC occurred within 10-50 min after injection and lasted 90-140 min. 
Maximal depressant effects were observed 30-60 min after 10 and 30 mg/kg.  
 
Depressant effects of UR-144 occurred within 10 min after administration and lasted 40-60 min. 
Maximal depressant effects of 10 and 30 mg/kg occurred 10-40 min after injection.  
 
Drug discrimination: 
e
 
 
XLR-11 (ED50 = 0.18 mg/kg), Δ
9
-THC (ED50 = 0.85 mg/kg) and UR-144 (ED50 = 0.45 mg/kg), 
amongst other synthetic cannabinoids tested, fully substituted for the discriminative stimulus 
effect of Δ9- THC (3 mg/kg).  
 
XLR-11 (1 mg/kg) fully substituted from 5 to 15 min after administration, and drug-appropriate 
responding was nearly absent by 60 min. No effect on response rate was observed for this dose of 
XLR-11. UR-144 (2.5 mg/kg) fully substituted at 15 and 60 min after administration, and drug-
appropriate responding was diminished to <40% after 4 h. No effect of UR-144 on the response 
rate was observed. 
 
No other adverse effects were observed at the doses and time points tested. 
Gatch et al.
21
 
 
a
 Ref
13
: Male ICR mice; intravenous injection in tail vein; spontaneous activity measured 5 min after drug injection 
for 10 min (two 4-beam infrared arrays, horizontal movement); warm water tail withdrawal procedure assessed with 
55 °C warm water and tested at 20 min post-injection; rectal temperature measured with digital thermometer 30 min 
after injection; ring immobility: at 40 min post-injection, mice were placed on elevated ring set-up and the amount of 
time the animals remained motionless during a 5 min period was recorded. 
 
b
 Ref
13
: Male C57/Bl6J inbred mice; trained to respond on one of the two levers following intraperitoneal (i.p.) 
administration of 5.6 mg/kg Δ9-THC and to respond on the other lever following i.p. vehicle injection according to a 
fixed ratio 10 (FR10) schedule of food reinforcement, under which 10 consecutive responses on the correct (injection-
appropriate) lever resulted in delivery of a food pellet; 15 min daily training sessions were held; once substitution 
tests with each compound were completed, a further assessment of rimonabant antagonism of the effects of 5.6 mg/kg 
XLR-11 and UR-144 was included. Three mg/kg rimonabant was injected i.p. 10 min prior to i.p. injection of XLR-
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11 or UR-144.  
 
c
 Ref
5
: male Wistar rats; biotelemetry transmitters placed in the peritoneal cavity; drugs administered (i.p.) in an 
ascending dose sequence (0.1, 0.3, 1, 3 mg/kg) (10 mg/kg if required) at the same time of day; data for heart rate and 
body temperature gathered at 1000 Hz (15 or 30 min bins). Data were corded for 6 h post-injection. 
 
d
 Ref
21
: Male ND4 Swiss-Webster mice (~8 weeks old); 16 infrared beams were located in the horizontal direction; 
dose range tested: Δ9-THC (1-30 mg/kg), UR-144 (1-30 mg/kg), XLR-11 (1-30 mg/kg), and others, immediately 
before testing. Horizontal activity (interruption of photocell beams, ambulation counts) was measured for 8 h within 
10-min periods; behavioural observations of each mouse were recorded at 30, 120, and 480 min after the highest dose 
tested.  
 
e
 Ref
21
: Male Sprague-Dawley rats; trained to discriminate Δ9-THC (3 mg/kg) from vehicle  using a two-lever choice 
methodology; each training session lasted 10 min; test drugs (amongst others): intraperitoneal injections of UR-144 
(0.1-5 mg/kg, 30 min before start) and XLR-11 (0.05-1 mg/kg, 15 min before start). Δ9-THC (3 mg/kg) controls were 
tested before the start of each compound evaluation. 
 
5. Toxicology 
The potential genotoxic properties of XLR-11 have been investigated using a variety of 
genotoxicity systems.
24
 Gene mutations were not induced in bacterial mutagenicity tests with 
Salmonella typhimurium strains. In vitro single cell gel electrophoresis (SCGE) assays with human 
lymphocytes and with buccal- and lung-derived human cell lines revealed induction of DNA 
damage but was considered unrelated to oxidative damage. The addition of liver enzyme 
homogenate (S9 mix) confirmed that DNA-reactive intermediates were not formed as a 
consequence of XLR-11 biotransformation and that the addition of bovine serum albumin might 
have contributed to potential detoxification via protein binding. XLR-11 (tested between 25 μM 
and 150 μM) caused the formation of micronuclei in human mitogen-stimulated lymphocytes and 
in TR-146 cells at high doses, which reflected chromosomal aberrations. Furthermore, 5 mg and 
20 mg samples of XLR-11 were vaporized to assess DNA stability in human-derived lung 
fibroblasts (A-549) and buccal (TR-146) cells via implementation of a gas-liquid interface in order 
to mimic drug exposure by inhalation. The observation of DNA instability suggested that exposure 
of drug vapor to cells in the respiratory tract may cause tumors and that further studies were 
needed to investigate further.
24
 
 
6. Adverse Reactions in Humans 
Adverse reactions associated with products determined to contain XLR-11 are summarized in 
Table 4 below. The total number of cases reported in the scientific literature is relatively small. 
The non-fatal cases feature the association with acute kidney injuries but the ability to identify a 
casual link in all cases with XLR-11 proved challenging and other possible etiologies might have 
to be considered as well. Commonly reported adverse reactions associated with a range of 
synthetic cannabinoids frequently include agitation, cardiovascular events including tachycardia 
and hypertension, hallucination, nausea/hyperemesis, seizures and hypokalaemia. Chest pain, 
myoclonia and psychiatric complications were also reported.
25, 26
 
 
 
 
 
  
38
th
 ECDD (2016) Agenda item 4.12  XLR-11 
 
 
 
Page 17 of 33 
Table 4. Case reports associated with the involvement of XLR-11 reported in the scientific literature. 
Year Cases Patient, 
age 
Context/clinically related comments (examples) Ref 
2012 16 15M, 1F Fifteen males aged 15-33 years (median: 18.5 years) and one female 
aged 15 years; Acute kidney injury associated with the intake of products 
containing synthetic cannabinoids in six US States between March 2012 
and December 2012; all 16 patients initially visited emergency 
departments and subsequently were hospitalized.  
 
Clinical features: 
 
Nausea and vomiting in 15/16 cases; Twelve patients reported 
abdominal, flank, and/or back pain. None reported pre-existing renal 
dysfunction or use of medication that might have caused renal problems.  
 
The highest serum creatinine concentrations (creatinine peak) among the 
16 patients ranged from 3.3 to 21.0 mg/dL (median: 6.7 mg/dL; normal 
0.6–1.3 mg/dL) and occurred 1-6 days after symptom onset (median: 3 
days). Urinalysis for 15 patients showed variable results: proteinuria 
(eight patients), casts (five), white blood cells (nine), and red blood cells 
(eight). Twelve patients underwent renal ultrasonography, nine of whom 
had a nonspecific increase in renal cortical echogenicity; none had 
hydronephrosis. Six of eight patients with a renal biopsy demonstrated 
acute tubular injury, and three of eight patients demonstrated features of 
acute interstitial nephritis. Kidney function recovery was apparent within 
3 days of creatinine peak in most patients. However, five of the 16 
patients required haemodialysis, and four patients received 
corticosteroids; none died. Other infectious, autoimmune, 
pharmacologic, or other toxic causes of AKI were not found. 
 
Product used by 5/16 patients, including two patients who used the same 
product, contained XLR-11. XLR-11 and/or the N-pentanoic acid 
metabolite) was detected in five of the seven cases for whom clinical 
specimens were available.  
 
The consistent finding of XLR-11 in product samples and clinical 
specimens was suggested to include alternative explanations: XLR-11, a 
metabolite, or a contaminant associated with it might be responsible for 
AKI in these patients, or its presence might simply reflect the widespread 
use of this particular compound in SC products during the study period 
rather than a causal association with AKI.  
CDC
3
 
2013 1 26M Acute kidney injury. Case also included in CDC report above.
3
 Patient 
presented to the emergency department with one day of abdominal pain, 
nausea, vomiting and lower back pain. Vital signs: 97.7° F; heart rate: 54 
bpm; blood pressure: 151/40 mmHg; respiratory rate: 16 breaths per min 
with 100% SatO2. Laboratory evaluation proved to be remarkable for a 
14.4 K/mm3 WBC, 5.38 mg/dL serum creatinine, 30 mg/dL blood urea 
nitrogen (BUN), and urinalysis with 1+ protein and trace blood. On Day 
2 in the hospital, creatinine and BUN peaked at 7.74 and 39 mg/dL; 
discharged after six days in the hospital with AKI of unknown etiology 
and serum creatinine of 3.09 mg/dL. Twenty three days later his serum 
creatinine was 1.1 mg/dL. 
 
Product and biofluids analysis confirmed the presence of XLR-11 and 
UR-144; patient reporting use of this branded product two or three times 
a day for approximately one year and had used the product on the 
morning of his presentation.  
Thornton et al.
27
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2014 9 All M Acute kidney injury. Cases appear to be related to those mentioned in 
CDC report above.
3
 Males aged 15-27 years (median, 18 years).  
 
Nine patients: initial symptoms acute onset of severe nausea, emesis, and 
back or abdominal pain (89%). In cases who recalled their last exposure, 
they reported symptom onset between approximately 30 min and 24 h 
(median: 8-12 h) after smoking a synthetic cannabinoid product. One 
patient reported gross hematuria, and one presented with uremic 
encephalopathy (blood urea nitrogen, BUN. 177 mg/dL). All required 
hospitalization.  
 
All patients had elevated peak systolic blood pressure (median, 154 mm 
Hg; range, 138-172 mm Hg). Initial BUN concentration ranged from 24 
to 177 mg/dL (median, 42 mg/dL), and peaked at 28-177 mg/dL 
(median, 42 mg/dL). Initial serum creatinine concentration ranged from 
2.6 to 17.7 mg/dL (median, 6.6 mg/dL); it peaked 2-7 days (median, 4 
days) after symptom onset (median peak Cr, 7.9 [range, 2.6-17.7 
mg/dL]). Eight patients demonstrated leukocytosis (89%). Renal 
ultrasound performed on eight patients revealed a nonspecific increase in 
cortical echogenicity without hydronephrosis for seven (88%) patients. 
 
For two patients, peak creatinine persisted for 4 days, and recovery of 
renal function occurred after patients received corticosteroids or 
hemodialysis.  
 
Four patients had smoked the synthetic cannabinoid product with a total 
of five other contacts, none of whom reported illness to the cases. 
Synthetic cannabinoid products (n=2) and clinical specimens (n=9) were 
obtained from five patients. XLR-11 and the N-pentanoic acid metabolite 
was detected in one serum sample with an interval of last use and 
sampling of 44 h. Treatment for the majority of cases: fluid management.  
 
Whether XLR-11 caused acute kidney injury could not be 
unambiguously concluded.  
Buser et al.
28
 
2014 1 22M Intoxication and involvement in a road traffic accident. Driver displayed 
a lethargic attitude and behavior with slow speech, low body 
temperature, rigid muscle tone, normal pulse, lack of horizontal and 
vertical gaze nystagmus, nonconvergence of the eyes, dilated pupil size, 
and normal pupillary reaction to light. Blood analysis revealed a blood 
concentration of 1.34 ng/mL. 
Lemos et al.
15
 
2014 18 All male Intoxication and impaired driving. Mean age: 25 y (range 17-42, median 
23.0). Eight cases revealed detection of XLR-11 (blood) and 4 cases 
showed the presence of UR-144 and XLR-11 (blood). Slurred speech, 
lack of convergence, and body and eyelid tremors were most consistently 
noted during interview. Horizontal gaze nystagmus, bloodshot and 
watery eyes were also described.  
Louis et al.
14
 
2014 1 33M Acute cerebral ischemia and infarction following consumption of a 
herbal product containing XLR-11. His vital signs upon arrival were BP, 
163/63 mmHg; pulse, 100/ min; respiration, 16/min; oxygen saturation, 
99% on room air; and afebrile. The patient was right-handed, and his 
initial physical examination was significant with right facial weak- 
ness/flattening of the right nasolabial fold, minor right hemiparesis, 
dysarthria, aphasia, and a mild right pronator drift. The National 
Institutes of Health Stroke Scale (NIHSS) score was 5, which improved 
to a score of 3 within an hour. A repeat head CT, performed the next day, 
showed acute infarction in the left insular cortex. Analysis of herbal 
product revealed the presence of XLR-11 but it was not detected in blood 
Takematsu et al.
4
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and urine collected 1 h after inhalation.  
2015 2 29F, 32F Case 1: 29F found dead with reported signs of intoxication and agitation 
the day before; known to be user of synthetic cannabinoid products; 
diphenhydramine (81 ng/mL) and XLR-11 (1.4 ng/mL) detected in 
peripheral blood. Medical examiner certified the cause of death as 
synthetic cannabinoid toxicity and the manner of death as accident. 
 
Case 2: 32F with history of drug abuse, including methamphetamine, 
heroin, and synthetic cannabinoids, presented to the emergency room 
with chest pain, nausea, and agitation. She was diagnosed with anxiety 
and left the hospital; was later found unresponsive and died.  
 
Remarkable pathological findings at autopsy were significant pulmonary 
edema and congestion, along with acute visceral congestion and mild 
pulmonary anthracosis. XLR-11 detected (0.6 ng/mL). Naloxone was 
administered during resuscitation attempts. Medical examiner ruled the 
cause and manner of death as undetermined, with significant findings of 
positive toxicology for XLR-11.  
Shanks et al.
29
 
 
7. Dependence Potential 
A. Animal Studies 
No information available.  
B. Human Studies 
No information available. 
 
8. Abuse Potential 
A. Animal Studies 
The in vivo data summarized in Table 3 suggest that XLR-11 displays abuse 
liability.  
B. Human Studies 
No information available. 
 
9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
Not applicable. 
 
10. Listing on the WHO Model List of Essential Medicines 
XLR-11 is not listed on the WHO Model List of Essential Medicines. 
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11. Marketing Authorizations (as a Medicinal Product) 
XLR-11 is not marketed as a medicine. 
 
12. Industrial Use 
XLR-11 has no reported industrial use. 
 
13. Non-Medical Use, Abuse and Dependence 
Household or subpopulation surveys that specifically probe for prevalence of XLR-11 are 
currently not available in the published literature.  
 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances 
 
14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
The majority of available synthetic cannabinoid products (including those identified to 
contain XLR-11) is sold in the form of herbal mixtures, and designed for smoking 
purposes. It is common for retailers to purchase bulk quantities of the synthetic substance 
and to add the synthetic material to a variety of vegetable matter as the plant base. Products 
sold as herbal smoking mixtures frequently change in drug composition and quantity, often 
without indications on product labels.
1, 30
   
 
The consumption of these products might be attractive to a variety of users, such as regular 
users of cannabis and those who might wish to avoid drug-testing procedures resulting in 
positive cannabis findings. Ease of access, and perceived lack of control might equally be 
of interest to some users. The high potency associated with many synthetic cannabinoids 
carries the risk of accidental overdose and potentially severe adverse events but 
information specific to XLR are limited. Cases specific to XLR-11 have been summarized 
in Table 4 of Section 6 including examples of impaired driving under the influence of 
XLR-11.  
 
15. Licit Production, Consumption and International Trade 
XLR-11 is available as standard reference material and produced for scientific research by 
a number of commercial suppliers. Other uses are not known. 
 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the EMCDDA’s European Early-Warning System on new 
psychoactive substances that XLR-11 (first reported in 2012) was encountered in seizures or 
as a used substance in Greece, France, Bulgaria, United Kingdom, Cyprus, Ireland, 
Romania, Italy, Czech Republic, Latvia, Finland, Croatia, Sweden, Denmark, Spain, 
Belgium, Germany, Norway, Austria, Slovenia, and Hungary.
31
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In 2012, XLR-11 has been reported to UNODC by Norway and Portugal.
32
 XLR-11 was 
reported 97 times to the UNODC Early Warning Advisory on New Psychoactive Substances 
by 39 Countries since 2012 (2015 data not complete yet at the time of this writing). The 
highest number of reports was received in 2014 (Dr. Justice Tettey, UNODC, personal 
communication).
33
 In South Korea, XLR-11 has been reported to represent the most 
frequently seized synthetic cannabinoid in 2013 with a total number of synthetic 
cannabinoid seizures reaching more than 40.
34
  
 
Between 2009 and June 2013, 26 species of synthetic cannabinoids were identified by the 
the National Forensic Service in South Korea in materials seized mainly by the Police 
Agency and the Prosecutor’s Office in South Korea.34 Another report stated that until 2014, 
XLR-11 was identified in 75 seized materials in 24 cases submitted to the National Forensic 
Service by the police or public prosecutor’s office.11 
 
XLR-11 appeared to be particularly prevalent in the United States since 2012. The National 
Forensic Laboratory Information System (NFLIS), which is dedicated to the collection of 
drug cases submitted by State and local laboratories in the United States, registered 19,795 
reports linked to XLR-11 in the period between January 2010 and June 2013. The January - 
June 2013 period alone accounted for 11,273 reports.
35
 The NFLIS 2014 midyear report 
(revised in March 2016) documented that XLR-11 featured in 6,316 out of 18,823 reports on 
synthetic cannabinoids compared to a total number of 660,078 reported for the top 25 drugs 
(e.g. cannabis/THC = 230,330 reports).
36
 In comparison, the NFLIS 2015 midyear report 
documented that XLR-11 featured in 3,769 out of 17,053 reports on synthetic cannabinoids. 
The total number of reports for the top 25 was 659,842 (cannabis/THC = 204,030 reports).
37
   
 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
17. Current International Controls and Their Impact 
XLR-11 is not controlled under the 1961, 1971 or 1988 United Nation Conventions. 
 
18. Current and Past National Controls 
The EMCDDA received information from the National Focal Points that XLR-11 is 
controlled in the following countries:
31
 Belgium, Czech Republic, Denmark, Estonia, 
Finland, Hungary, Lithuania, Portugal, Romania, Turkey, United Kingdom. XLR-11 is also 
controlled in China
38
 and the United States.
39-41
 
 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on 
the Scheduling of the Substance 
Not applicable.  
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances for the 38th ECDD: Evaluation of XLR-11 
 
Data was obtained from 47 Member States (6 AFR, 2 EMR, 26 EUR, 7 PAH, 1 SEAR and 5 
WPR).  
 
A total of 39 Member States (4 AFR, 2 EMR, 20 EUR, 7 PAH, 1 SEAR and 5 WPR) answered the 
questionnaire for XLR-11. Of these, 23 respondents (1 AFR, 2 EMR, 17 EUR, 2 PAH and 1 
WPR) had information on this substance.  
 
LEGITIMATE USE  
 
There were 20 countries that reported no approved medical products containing XLR-11 for 
human or veterinarian indications. There was also no reported industrial use in 17 countries.  
 
XLR-11 is currently being used in medical or scientific research in one country for metabolism 
and abuse potential research. Importation is the origin/source of XLR-11 when used for legitimate 
non-medical/non-scientific use.  
 
XLR-11 was not reported to be used for any cultural, religious or ceremonial purposes in 19 
countries.  
 
EPIDEMIOLOGY OF NON-MEDICAL/NON-SCIENTIFIC USE – USE FOR 
PSYCHOACTIVE PURPOSES OR RECREATIONAL DRUG USE 
 
There were 13 countries that reported XLR-11 as being misused for its psychoactive properties (as 
a recreational drug). Common routes of administration for non-medical/non-scientific purposes are 
smoking (9 countries), oral (2 countries), inhalation (2 countries) and sniffing (1 country). The 
main route of administration for XLR-11 was reported as smoking (5 countries) and oral (1 
country).  
 
The most common formulation reported for non-medical/non-scientific purposes was powder (5 
countries), followed by tablets (1 country). Another common formulation reported was herbal 
mixtures or plant material impregnated with the XLR-11 (11 countries). One country mentioned 
that it was prepared in this way to resemble cannabis.  
 
There were 9 countries which reported that the source of XLR-11 for non-medical/non-scientific 
use was smuggling.  
 
Specific subpopulations known to misuse XLR-11 included cannabis users (1 country) and youth 
(1 country).  
 
The level of negative health-impact originating from this substance's non-medical consumption 
was reported as either negligible (3 countries), substantial (1 country) or serious (4 countries). For 
the countries that indicated a substantial or serious level of negative health-impact, they specified 
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that it was due to the association of XLR-11 with adverse effects (including intoxications, kidney 
injuries/toxicity, collapses, psychosis) and fatalities.  
 
One country reported emergency room/department visits related to the non-medical use of XLR-
11. They had 1 case in 2012 and 1 case in 2013, in both instances other substances were detected.  
 
The adverse effects which presented for XLR-11 at the emergency room/department included 
dizziness, cardiac and circulatory troubles, vomiting, acute psychosis. One country commented 
that neurological and cardiovascular adverse effects have been noted following XLR-11 ingestion. 
They also stated that an association between XLR-11 and acute kidney injury has been reported.  
 
In regards to the mortality rate, data was provided by 1 country where they had a case in 2013 
where only XLR-11 was involved.  Another country reported 10 cases in 2010 to 2015 where 
other substances were also involved. One country commented that there may be a higher number 
of cases because in their country there is no reporting obligation by hospitals, poison centers etc. 
 
STATUS OF NATIONAL CONTROL AND POTENTIAL IMPACT OF 
INTERNATIONAL CONTROL 
 
There were 19 countries reported that XLR-11 was under national control. The legislation the 
control is based upon included Medicines Act (3 countries), Controlled Substances Act (12 
countries), Criminal Law Act (1 country) and other specific legislation (2 countries stated that it 
was specific legislation for new psychoactive substances). In two countries the current control is a 
temporary measure. Another country reported that it is not currently under control but an 
amendment to their legislation on new psychoactive substances is currently in preparation. There 
were no challenges to implementing controls for XLR-11 reported. 
 
The scope of the controls includes production (16 countries), manufacturing (17 countries), 
exporting (16 countries), importing (18 countries), distribution (17 countries), use (11 countries) 
and possession (16 countries).  
 
Reported illicit activities involving XLR-11 include manufacture of the substance by chemical 
synthesis (1 country), production of consumer products (2 countries), trafficking (8 countries), 
smuggling (1 country), diversion (1 country), domestic internet sales (1 country), internet sales 
from abroad (5 countries), internet sales from unknown locations (4 countries) and finally sales to 
people who use this substance (4 countries).  
 
There were 14 countries which completed the section on the number of seizures. The combined 
number of seizures was 11,109 (2014), 7,111 (2015) and 1,227 (2016 to date). One country 
commented that they had noticed a decline of cases as soon as the substance was placed under 
control by national legislation. 
 
If XLR-11 was placed under international control, 22 countries responded that they would have 
the capacity to enforce the control at the national level. There were 22 countries which responded 
that they would have the forensic laboratory capacity to analyse the substance. 
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Annex 2: Representative examples of studies associated with the 
detection and chemical analysis of XLR-11 (amongst other 
substances) published in the scientific literature. 
 
Table 1. Representative examples of studies published in the scientific literature associated with the analysis of 
XLR-11 amongst other substances 
a, b
 
Techniques 
c
 Comment  Reference 
GC-MS, LC-TOF-MS, 
NMR 
Analysis of herbal products seized in June/July 2012. Choi et al.
1
 
ELISA XLR-11 showed cross-reactivity with JWH-200 calculated at 
a 0.03% level.  
Rodrigues et al.
2
 
GC-MS Analysis of 3481 items seized between January 2010 and 
December 2012 (1321 cases). XLR-11 was detected in 
~25% of the items. 
Seely et al.
3
 
LC-TOF-MS Analysis of herbal samples. Shanks et al.
4
 
GC-MS, LC-QTOF-MS, 
NMR 
Characterization of seized samples.  Shevyrin et al.
5
 
GC-MS, LC-DAD, LC-
MS, 
DART-TOF-MS, NMR 
Analysis of herbal samples purchased via the Internet 
between October 2011 and April 2012. 
Uchiyama et al.
6
 
LC-QTOF-MS/MS Urine analysis of XLR-11 and UR-144 metabolites following 
administration of test drugs in male ICR mice. 
Wiley et al.
7
 
LC-QqQ-TOF-MS In vitro metabolism study using pooled human hepatocytes. Wohlfarth et al.
8
 
LC-QTOF-MS, GC-MS, 
FT-IR 
Analysis of seized resinous samples. Zuba et al.
9
 
CE, MEKC-MS/MS Method development and application to herbal samples. Akamatsu et al.
10
 
LC-MS/MS Method development and application to 498 authentic oral 
fluid samples. 
Amaratunga et al.
11
 
LC-TOF-MS Detection of XLR-11 in two products and one clinical serum 
sample from 2012. 
Buser et al.
12
 
Immunoanalysis Method validation for synthetic cannabinoids in urine and 
application to authentic urine samples. 
Castaneto et al.
13
 
GC-MS Analysis of 140 samples species seized between 2009 and 
2013. 
Chung et al.
14
 
LC-MS/MS Method development and application to authentic serum 
samples. 
Huppertz et al.
15
 
Presumptive color test Evaluation of Brady’s reagent (2,4-dinitrophenylhydrazine). Isaacs
16
 
GC-MS, LC-MS/MS, 
NMR 
Analysis of herbal plant products obtained from test 
purchases. 
Langer et al.
17
 
EI-MS, LC-MS/MS Detection in whole blood from an impaired driver.  Lemos et al.
18
 
LC-MS/MS Detection of XLR-11 in clinical samples obtained from 
impaired driving cases collected between June 2012 and 
September 2013. 
Louis et al.
19
 
ELISA, LC-MS/MS Method validation and application to authentic urine samples. Mohr et al.
20
 
LC-MS/MS Method development for analysis in urine. Scheidweiler et al.
21
 
GC-MS Detection of XLR-11 in a product involved in serious adverse 
reaction. 
Takematsu et al.
22
 
TLC, NMR, m.p., 
elemental analysis; ESI-
MS 
General characterization following synthesis. Banister et al.
23
 
IMS, DART-QTOF-MS Analysis of standard reference material. Gwak et al.
24
 
GC-(EI/CI)-MS/MS Analysis of standard reference material. Gwak et al.
25
 
LC-IT-MS In vitro metabolism study using HepaRG cells and analysis of 
clinical urine sample. 
Kanamori et al.
26
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Miniature MS Analysis of standards using two ambient ionization methods 
(paper spray and extraction spray). 
Ma et al.
27
 
LC-TOF-MS, GC-MS Analysis of standards. Marginean et al.
28
 
LC-DAD, GC-MS Analysis of 4,127 packages (31 different brands) seized in 
March 2012. XLR-11 was detected in some but not all items. 
Moosmann et al.
29
 
LC-MS/MS Analysis of hair samples obtained from laboratory personnel 
handling herbal mixtures containing synthetic cannabinoids. 
XLR-11 detected in hair samples from 2/8 participants. 
Moosmann et al.
30
 
LC-MS/MS Analysis of hair samples obtained from users and detection 
of XLR-11 in 14 samples. 
Park et al.
31
 
LC-MS/MS Analysis of biofluids in two fatalities associated with XLR-11. Shanks et al.
32
 
Immunoanalysis Application to herbal products. Uchiyama et al.
33
 
LC-MS/MS Method development and application to authentic samples 
(XLR-11 not detected in case samples). 
Adamowicz and 
Tokarczyk
34
 
LC-Q-MS Evaluation of matric effects in spiked blank blood samples. Adamowicz and 
Wrzesień, 
35
 
LC-DAD, LC-Q-MS, SFC-
MS 
Method development using standards. Breitenbach et al.
36
 
LC-MS/MS Method development and screening of 526 urine samples 
obtained from suspects of impaired driving between June 
2012 and August 2013.  
Davies et al.
37
 
Electroanalysis, GC-MS, 
LC-MS  
Method development and application to seized samples. Dronova et al.
38
 
LC-QTOF-MS In vitro metabolism study and application to 18 authentic 
urine samples obtained from users.  
Jang et al.
39
 
ATR-IR, Raman, NMR Analysis of 221 seized samples. Jones et al.
40
 
FT-ICR-MS Analysis of nine herbal samples.  Kill et al.
41
 
LC-Q-Orbitrap In vitro metabolism study using human liver microsomes and 
recombinant CYP enzymes.  
Nielsen et al.
42
 
a 
As of August 2016. 
 
b
 The term ‘herbal’ product typically refers to a variety of vegetable plant matters that have been spiked with the 
synthetic drug and do not refer to a natural product containing these substances.
 
 
c
 GC: gas chromatography; MS: mass spectrometry; LC: liquid chromatography (various forms); TOF: time-of-
flight; NMR: nuclear magnetic resonance spectroscopy; ELISA: enzyme-linked immunosorbent assay; DAD: diode 
array detection; DART: direct analysis in real time; QTOF: quadrupole-time-of-flight; QqQ: triple quadrupole; FT-
IR: Fourier transform infrared spectroscopy; CE: capillary electrophoresis; MEKC: micellar electrokinetic 
chromatography; MS/MS: tandem mass spectrometry; EI: electron ionization; m.p.: melting point; IMS: ion mobility 
spectrometry; CI: chemical ionization; IT: ion trap; Q: quadrupole; SFC: supercritical fluid chromatography; ATR-
IR: attenuated total reflectance IR; FT-ICR-MS: Fourier transform ion cyclotron mass spectrometry. 
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